Puma Biotechnology (PBYI) Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PBYI Community Fair Values
Create NarrativeSee what 23 others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Puma Biotechnology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.78 |
| 52 Week High | US$7.85 |
| 52 Week Low | US$2.69 |
| Beta | 1.18 |
| 1 Month Change | 29.67% |
| 3 Month Change | 27.33% |
| 1 Year Change | 175.89% |
| 3 Year Change | 157.62% |
| 5 Year Change | -22.74% |
| Change since IPO | -42.37% |
Recent News & Updates
Recent updates
With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case
Dec 09
Puma Biotechnology's (NASDAQ:PBYI) Shareholders May Want To Dig Deeper Than Statutory Profit
Nov 13Puma Biotechnology: Step By Step In Making A Transition
Nov 10Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock Catapults 26% Though Its Price And Business Still Lag The Market
Oct 18Does Puma Biotechnology (NASDAQ:PBYI) Have A Healthy Balance Sheet?
Sep 11Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock Catapults 43% Though Its Price And Business Still Lag The Market
Aug 12We Ran A Stock Scan For Earnings Growth And Puma Biotechnology (NASDAQ:PBYI) Passed With Ease
Aug 09Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Fly 25% But Investors Aren't Buying For Growth
May 20Puma Biotechnology: Initiating Hold Rating With Limited Near-Term Upside And Uncertain Pipeline Potential
Apr 11Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 26%
Mar 10
Alisertib Trials And International NERLYNX Approvals Will Expand Market, But Single Product Dependence And Safety Concerns Could Limit Gains
Strategic collaborations and regulatory approvals in international markets are expected to drive global revenue growth and increase overall sales.Insufficient Growth At Puma Biotechnology, Inc. (NASDAQ:PBYI) Hampers Share Price
Jan 14Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward
Dec 16Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest
Nov 14Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?
Sep 07Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop
Aug 15The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%
Jun 07Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today
Jun 05We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings
May 09Puma Biotechnology: A Story In Flux Heading Into Mid-2024
May 05Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?
Apr 10Shareholder Returns
| PBYI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 12.8% | 1.6% | 3.4% |
| 1Y | 175.9% | 46.8% | 29.7% |
Return vs Industry: PBYI exceeded the US Biotechs industry which returned 46.8% over the past year.
Return vs Market: PBYI exceeded the US Market which returned 29.7% over the past year.
Price Volatility
| PBYI volatility | |
|---|---|
| PBYI Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: PBYI has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PBYI's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 179 | Alan Auerbach | www.pumabiotechnology.com |
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer.
Puma Biotechnology, Inc. Fundamentals Summary
| PBYI fundamental statistics | |
|---|---|
| Market cap | US$396.84m |
| Earnings (TTM) | US$31.11m |
| Revenue (TTM) | US$228.37m |
Is PBYI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PBYI income statement (TTM) | |
|---|---|
| Revenue | US$228.37m |
| Cost of Revenue | US$58.16m |
| Gross Profit | US$170.21m |
| Other Expenses | US$139.10m |
| Earnings | US$31.11m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.61 |
| Gross Margin | 74.53% |
| Net Profit Margin | 13.62% |
| Debt/Equity Ratio | 17.3% |
How did PBYI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/10 21:59 |
| End of Day Share Price | 2026/04/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Puma Biotechnology, Inc. is covered by 13 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Geoffrey Meacham | BofA Global Research |
| Yigal Nochomovitz | Citigroup Inc |
| Paul Choi | Goldman Sachs |